Asia
Jiangsu Kanion Pharmaceutical Gets Greenlight for Rheumatoid Arthritis Drug Trial
Jiangsu Kanion Pharmaceutical (SHA:600557) obtained China's regulatory approval to start phase three clinical trials for Qingshen Tongluo granules.The traditional medicine is indicated for rheumatoid arthritis, according to a filing with the Shanghai bourse.Shares of the pharmaceutical company closed 1% lower Monday.
SHA:600557
